Pharsight

1. Flector patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5607690	IBSA	External anti-inflammatory and analgesic plaster preparation	Apr, 2019 (5 years ago)

Market Authorisation Date: 31 January, 2007

Treatment: NA

Dosage: SYSTEM;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.013	26 Jun, 2015	1		13 Apr, 2019	Extinguished

Strength	Dosage	Availability
1.3%	SYSTEM;TOPICAL	Prescription

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7723390	IBSA	Pharmaceutical formulations for thyroid hormones	Mar, 2024 (a month ago)
US7691411	IBSA	Pharmaceutical formulae for thyroid hormones and procedures for obtaining them	Mar, 2024 (a month ago)

Market Authorisation Date: 01 August, 2007

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
75 mcg and 150 mcg	29 Dec, 2017	1	28 Oct, 2020	14 Mar, 2024	Deferred
88 mcg, 100 mcg and 125 mcg	01 Aug, 2019	1	06 Jan, 2021	14 Mar, 2024	Eligible
112 mcg	18 Dec, 2020	1	16 Apr, 2021	14 Mar, 2024	Eligible
200 mcg	30 Dec, 2021	1	09 Nov, 2022	14 Mar, 2024	Eligible
137 mcg and 175 mcg	04 Nov, 2022	1	02 May, 2023	14 Mar, 2024	Eligible

Application	Filing Date	Opposition Party	Legal Status

EP17794903A	2021-04-21	Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.	Granted and Under Opposition

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11096913	IBSA	High-stability packaged solutions of T4 thyroid hormone	Feb, 2037 (12 years from now)
US10537538	IBSA	High-stability packaged solutions of T4 thyroid hormone	Feb, 2037 (12 years from now)
US11241382	IBSA	Administration regimen of compositions of T4 thyroid hormone with high oral absorption	Sep, 2039 (15 years from now)

Market Authorisation Date: 15 December, 2016

Treatment: Treatment of hypothyroidism by oral administration of l-thyroxine to a patient on an empty stomach 15 minutes before breakfast

Dosage: SOLUTION;ORAL